An Expanded Access Program for SYN023 in Rabies Treatment
Sponsor-Initiated Expanded Access Program (SYN023-EAP-001) for SYN023 (Zamerovimab + Mazorelvimab): Compassionate Use of SYN023 in Patients With Confirmed or Suspected Life-Threatening Rabies Infection
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 9, 2026
CompletedFirst Posted
Study publicly available on registry
July 16, 2026
CompletedJuly 17, 2026
July 1, 2026
July 9, 2026
July 16, 2026
Conditions
Keywords
Interventions
SYN023 may be administered with rabies treatments according to the local standard of care; local standard of care may include the Milwaukee Protocol if the treating clinician and patient so choose.
Eligibility Criteria
You may qualify if:
- Must be ineligible for or lack access to other investigational or approved therapies
- Must have no available alternative curative treatment options
You may not qualify if:
- \- Clinical contraindications identified on an individual basis by the treating critical care clinician
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 9, 2026
First Posted
July 16, 2026
Last Updated
July 17, 2026
Record last verified: 2026-07